Phosphatidylinositol 3-kinase alpha, beta, and delta (PI3Kα, PI3Kβ, PI3Kδ)

Phosphatidylinositol 3-kinase alpha, beta, and delta (PI3Kα, PI3Kβ, PI3Kδ) are catalytic subunits of Class I phosphoinositide 3-kinases, a family of lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI 4,5-P₂) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP₃)[1][4][7]. This triggers downstream signaling primarily via AKT and mTOR, modulating crucial cellular processes including cell proliferation, survival, motility, and metabolism[1][2][6]. PI3Kα is frequently mutated in cancers (most commonly as PIK3CA), PI3Kβ is involved in platelet aggregation and certain GPCR-mediated signals, while PI3Kδ is critically important in immune cells[4][5]. These enzymes are considered highly validated therapeutic targets in oncology and immune-mediated conditions, with multiple drugs approved for clinical use and several others under investigation[6][4].

Other names

PI3K alpha (PIK3CA, p110α)PI3K beta (PIK3CB, p110β)PI3K delta (PIK3CD, p110δ)Phosphoinositide 3-kinase alpha/beta/deltaClass IA PI3K

Competitive inhibition of the ATP-binding site (for small-molecule inhibitors) Blockade of PI3K phosphorylation of PI 4,5-bisphosphate, preventing PIP3 generation and downstream AKT signaling